Merkel Cell Carcinoma

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
• MCC exhibits high radiosensitivity and immunogenicity.
• Immunotherapy, particularly immune checkpoint inhibitors, is the primary treatment for advanced MCC.

Purpose of the Study:

• To review the characteristics and management of Merkel cell carcinoma.
• To highlight recent innovations and areas of active investigation in MCC treatment.
• To discuss the role of immunotherapy and emerging biomarkers in MCC.

Main Methods:

• This is a review article, synthesizing existing research and clinical findings.
• The review covers epidemiology, pathology, diagnosis, and treatment modalities for MCC.
• Focus is placed on immunotherapy, neoadjuvant/adjuvant therapy, and biomarker research.

Main Results:

• Immune checkpoint inhibitors show promise in neoadjuvant or adjuvant settings for high-risk MCC.
• Emerging biomarkers for tumor burden are crucial for risk stratification and surveillance.
• Optimal duration of anti-PD-(L)1 therapy and second-line options for refractory MCC require further investigation.

Conclusions:

• Immunotherapy is a cornerstone in advanced Merkel cell carcinoma management.
• Biomarker research and further clinical trials are essential for refining MCC treatment strategies.
• Continued research is needed to address treatment resistance and optimize long-term outcomes.